Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Badanie badawcze u dzieci urodzonych jako małe i które pozostały małe. Leczenie to Somapacitan raz w tygodniu w porównaniu do Norditropin® raz dziennie

5 października 2026 zaktualizowane przez: Novo Nordisk A/S

Badanie mające na celu ustalenie dawki oceniające wpływ i bezpieczeństwo leczenia somapacitanem raz w tygodniu w porównaniu z codziennym stosowaniem produktu Norditropin® u dzieci z niskim wzrostem urodzonych z niskim wzrostem w stosunku do wieku ciążowego bez nadrabiania wzrostu do 2. roku życia lub starszych

The study compares 2 medicines used for the treatment of children who are born small and who stayed small: somapacitan given once a week (a new medicine) and Norditropin® given once a day (the medicine doctors can already prescribe).

Participants will either get somapacitan or Norditropin® - which treatment is decided by chance. Both participants and the study doctor will know which treatment the participants get. The study will last for 5 years. Participants will take either an injection once every week or once every day.

Przegląd badań

Status

Aktywny, nie rekrutujący

Warunki

Interwencja / Leczenie

Typ studiów

Interwencyjne

Zapisy (Rzeczywisty)

62

Faza

  • Faza 2

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

      • Algiers, Algieria, 16000
        • CHU Bab El Oued Pediatrics Dept
      • Algiers, Algieria, 16000
        • Endo and Diab Dept El Oued
      • Constantine, Algieria, 25000
        • endocrino-diabetology department, Hospital IBN BADIS.
      • Graz, Austria, 8036
        • Med. Univ. Graz -Klinische Abteilung f. Allgemeine Pädiatrie
      • Salzburg, Austria, A 5020
        • LKH Salzburg- Univ. Klinik f. Kinder- und Jugendheilkunde
      • Sankt Pölten, Austria, 3100
        • LKH St. Poelten, Kinder-und Jugendheilkunde
      • Vöcklabruck, Austria, 4840
        • Salzkammergut-Klinikum Vöcklabruck
    • Upper Austria
      • Linz, Upper Austria, Austria, 4020
        • Kepler Universitätsklinikum GmbH - Med Campus IV (vorm.LFKK)
      • Copenhagen Ø, Dania, 2100
        • Rigshospitalet Klinik for Vækst og Reproduktion Afsnit 5064
      • Tallinn, Estonia, 13419
        • Tallinn Children's Hospital
      • Tartu, Estonia, 50406
        • Tartu University Hospital Children's Clinic
      • Angers, Francja, 49100
        • Centre Hospitalier Universitaire D'Angers-2
      • Le Kremlin-Bicêtre, Francja, 94270
        • AP-HP-HOPITAL DE BICETRE_Service d'Endocrinologie pédiatrique
      • Marseille, Francja, 13005
        • Assistance Publique Hopitaux de Marseille-Hopital de La Timone-2
      • Marseille Cédex 05, Francja, 13385
        • Hopital de La Timone
      • Paris, Francja, 75015
        • Ap-Hp-Hopital Necker
      • Paris, Francja, 75015
        • Hôpital Necker
      • Toulouse, Francja, 31059
        • HOPITAL DES ENFANTS-HOPITAL PAULE DE VIGUIER - Pharmacie
      • Esplugues Llobregat(Barcelona), Hiszpania, 08950
        • Hospital Sant Joan de Déu
      • Santiago de Compostela, Hiszpania, 15706
        • Hospital Clínico de Santiago de Compostela
    • Kerala
      • Kochi, Kerala, Indie, 682041
        • Amrita Institute Of Medical Sciences & Research Centre
    • Maharashtra
      • Pune, Maharashtra, Indie, 411001
        • Jehangir Clinical Development Centre
    • New Delhi
      • New Dehli, New Delhi, Indie, 110029
        • All India Institute of Medical Sciences
      • Dublin, Irlandia, D12 N512
        • CHI Crumlin Dept of Endocrinology
      • Haifa, Izrael, 31096
        • Rambam MC - Department of Pediatrics A
      • Kfar Saba, Izrael, 44281
        • Meir MC - Department of Paediatrics
      • Petah Tikva, Izrael, 49202
        • Schneider MC - Endrocrinology and Diabetes
      • Fukuoka, Japonia, 830-0011
        • Kurume University Hospital, Pediatrics
      • Fukuoka-shi, Fukuoka, Japonia, 813-0017
        • Fukuoka Children's Hospital_Endocrinology and Metabolism
      • Fukuoka-shi, Fukuoka, Japonia, 813-0017
        • Fukuoka Children's Hospital
      • Fukuyama-shi, Hiroshima, Japonia, 721-8511
        • Fukuyama City Hospital_Department of Pediatrics
      • Kobe-shi, Hyogo, Japonia, 650-0047
        • Hyogo Prefectual Kobe Children's Hospital Dept. Metab & endo
      • Kobe-shi, Hyogo, Japonia, 650-0047
        • Hyogo Prefectual Kobe Children's Hospital_Metab & endo
      • Kyoto, Japonia, 602-8566
        • Univ.HP, Kyoto Pref Univ of Medicine, Dept. of Pediatrics
      • Nara-shi, Nara, Japonia, 630-8581
        • Nara Prefecture General Medical Center_ Nara-shi, Nara
      • Nara-shi, Nara, Japonia, 630-8581
        • Nara Prefecture General Medical Center_Pediatric
      • Niigata-shi, Niigata, Japonia, 951 8520
        • Niigata University Medical & Dental Hospital_Pediatrics
      • Osaka, Japonia, 534-0021
        • Osaka City General Hospital, Pediatric Endocrinology and Me
      • Osaka, Japonia, 594-1101
        • Osaka Women's and Children's Hospital
      • Saitama-shi, Saitama, Japonia, 330-8777
        • Saitama Children's Medical Center, Endocrinorogy&Metabolism
      • Tokyo, Japonia, 157 8535
        • National Center for Child Health and Dev, Endo and Metabo
      • Tokyo, Japonia, 113-8519
        • Institute of Science Tokyo Hospital
      • Tokyo, Japonia, 113-8519
        • Institute of Science Tokyo Hospital_Pediatrics
      • Tokyo, Japonia, 157 8535
        • National Center for Child Health and Development_Endo and Metabo
      • Tokyo, Japonia, 160-8582
        • Keio University Hospital_Pediatrics
    • Alberta
      • Edmonton, Alberta, Kanada, T6G 2B7
        • Stollery Children's Hospital
      • Bergen, Norwegia, 5021
        • Haukeland Universitetssykehus, Barneklinikken
      • Szczecin, Polska, 71-252
        • SPSK nr 1 im Prof. T Sokolowskiego
      • Warsaw, Polska, 04-730
        • Instytut ''Pomnik - Centrum Zdrowia Dziecka''
      • Izhevsk, Rosja, 426009
        • Republic Children's Hospital of Ministry of Health of Udmurt
      • Moscow, Rosja, 119435
        • Setchenov First Moscow State Medical University
      • Moscow, Rosja, 125373
        • RMAPE
      • Novosibirsk, Rosja, 630048
        • Children's clinical city hospital #1
      • Rostov-on-Don, Rosja, 344013
        • FSBEI of Higher Education "Rostov State Medical University"
      • Saint Petersburg, Rosja, 191144
        • SPSBHI City Children out-patient clinic #44
      • Samara, Rosja, 443079
        • Samara Regional Children Clinical Hospital n.a. N.N. Ivanova
      • Tomsk, Rosja, 634050
        • Siberian State Medical University
      • Belgrade, Serbia, 11000
        • University Children's Hospital Tirsova
      • Belgrade, Serbia, 11070
        • Institute for Mother and Child Health Care of Serbia
      • Kragujevac, Serbia, 34000
        • University Clinical Centre Kragujevac
      • Niš, Serbia, 18 000
        • Clinical Center in Nis
      • Novi Sad, Serbia, 21000
        • Institute for Health Care of Children and Adolescents
    • Alabama
      • Birmingham, Alabama, Stany Zjednoczone, 35233
        • Univ of AL at Birmingham_BRM
    • California
      • Orange, California, Stany Zjednoczone, 92868
        • Children's Hosp Of Orange
    • Idaho
      • Boise, Idaho, Stany Zjednoczone, 83712
        • St. Luke's Children's Endo
    • Minnesota
      • Minneapolis, Minnesota, Stany Zjednoczone, 55454
        • Univ of Minnesota M.C.H.
      • Saint Paul, Minnesota, Stany Zjednoczone, 55102
        • Children's Minnesota
    • New Jersey
      • Morristown, New Jersey, Stany Zjednoczone, 07962
        • Goryeb Children's Hospital
      • New Brunswick, New Jersey, Stany Zjednoczone, 08901
        • Rutgers-Rwjms
    • New York
      • Garden City, New York, Stany Zjednoczone, 11530
        • NYU Langone Hospital-LI
      • Mineola, New York, Stany Zjednoczone, 11501
        • NYU Langone Hospital-LI
      • New York, New York, Stany Zjednoczone, 10029
        • Icahn Sch of Med-Mt Sinai Hosp
    • Ohio
      • Cincinnati, Ohio, Stany Zjednoczone, 45229
        • CCHMC_Cinc
    • Oklahoma
      • Oklahoma City, Oklahoma, Stany Zjednoczone, 73104
        • Univ Oklahoma Sci Ctr OK City
    • Texas
      • Fort Worth, Texas, Stany Zjednoczone, 76104
        • Cook Children's Hospital-Hematology-Oncology
    • Washington
      • Tacoma, Washington, Stany Zjednoczone, 98405
        • MultiCare Inst for Res & Innov
      • Bern, Szwajcaria, 3010
        • Med. Kinder- und Poliklinik
      • Zurich, Szwajcaria, 8032
        • Kinderspital Endokrinologie, Zürich
      • Bangkok, Tajlandia, 10330
        • King Chulalongkorn Memorial hospital-Ped-Endocrinology
      • Bangkok, Tajlandia, 10330
        • King Chulalongkorn Memorial hospital_Ped-Endocrinology
      • Bangkok, Tajlandia, 10400
        • Phramongkutklao Hospital_Ped-Endo_Pediatrics
      • Dnipro, Ukraina, 49100
        • Dnipropetrovsk Regional Children's Clinical Hospital - Endocrinology department
      • Kharkiv, Ukraina, 61093
        • Kharkiv Regional Children's Clinical Hospital - Endocrinological department
      • Kyiv, Ukraina, 04114
        • Komisarenko Institute of Endocrinology and Metabolism of NAMSU - Department of paediatric endocrine pathology
      • Budapest, Węgry, 1023
        • Észak-Közép-budai Centrum, Szent János Kórház és Szakrendelő
      • Szeged, Węgry, 6720
        • Szegedi Tudományegyetem Gyermekgyógyászati Klinika
      • Florence, Włochy, 50139
        • IRCCS Meyer Firenze
      • Genova, Włochy, 16147
        • Ospedale Pediatrico Gaslini
      • Milan, Włochy, 20122
        • Ospedale Maggiore Policlinico UO Endocrinologia Diabetolgia
      • Roma, Włochy, 00165
        • Ospedale Pediatrico Bambino Gesu
      • Hull, Zjednoczone Królestwo, HU3 2JZ
        • Hull Royal Infirmary
      • Liverpool, Zjednoczone Królestwo, L12 2AP
        • Alder Hey Children's Hospital
      • London, Zjednoczone Królestwo, E1 1BB
        • Royal London Hospital_London
      • Manchester, Zjednoczone Królestwo, M13 9WL
        • Royal Manchester Children's Hospital
      • Riga, Łotwa, 1004
        • Children's Clinical University Hospital

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

2 lata do 11 lat (Dziecko)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  • Pre-pubertal children, boys:

    1. age between 2.5 and 11.0 years at screening.
    2. testes volume below 4 ml.
  • Pre-pubertal children, girls:

    1. age between 2.5 and 10.0 years at screening.
    2. Tanner stage 1 for breast development (no palpable glandular breast tissue).
  • Born small for gestational age (birth length and/or weight below -2 standard deviation scores) (according to national standards).

  • Impaired height defined as at least 2.5 standard deviations below the mean height for chronological age and gender at screening according to the standards of Centers for Disease Control and Prevention at screening.

  • Impaired height velocity defined as annualized height velocity below the 50th percentile for chronological age and gender according to the standards of Prader calculated over a time span of minimum 6 months and maximum 18 months prior to screening.

  • No prior exposure to growth hormone therapy or Insulin-like Growth Factor-I (IGF-I) treatment.

Exclusion Criteria:

  • Any known or suspected clinically significant abnormality likely to affect growth or the ability to evaluate growth with standing height measurements.
  • Children with hormonal deficiencies including suspected or confirmed growth hormone deficiency according to local practise.
  • Current inflammatory diseases requiring systemic corticosteroid treatment for longer than 2 consecutive weeks within the last 3 months prior to screening.
  • Children requiring inhaled glucocorticoid therapy at a dose of greater than 400 μg/day of inhaled budesonide or equivalents for longer than 4 consecutive weeks within the last 12 months prior to screening.
  • Concomitant administration of other treatments that may have an effect on growth, e.g but not limited to methylphenidate for treatment of attention deficit hyperactivity disorder.
  • Diagnosis of attention deficit hyperactivity disorder.
  • Prior history or presence of malignancy including intracranial tumours.

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Brak (otwarta etykieta)

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: Somapacitan 0.24 mg/kg/week

Same treatment in main period (26 weeks) and extension period I (26 weeks). Dosage of Somapacitan during extension period II will be determined based on the data from main phase.

Somapacitan injected under the skin once a week.

Eksperymentalny: Somapacitan 0.20 mg/kg/week

Same treatment in main period (26 weeks) and extension period I (26 weeks). Dosage of Somapacitan during extension period II will be determined based on the data from main phase.

Somapacitan injected under the skin once a week.

Eksperymentalny: Somapacitan 0.16 mg/kg/week

Same treatment in main period (26 weeks) and extension period I (26 weeks). Dosage of Somapacitan during extension period II will be determined based on the data from main phase.

Somapacitan injected under the skin once a week.

Aktywny komparator: Norditropin® 0.035 mg/kg/day

Same treatment in main period (26 weeks) and extension period I (26 weeks). Participants will switch to Somapacitan during extension period II. Dosage of Somapacitan during extension period II will be determined based on the data from main phase.

Norditropin® injected under the skin once a day.

Aktywny komparator: Norditropin® 0.067 mg/kg/day

Same treatment in main period (26 weeks) and extension period I (26 weeks). Participants will switch to Somapacitan during extension period II. Dosage of Somapacitan during extension period II will be determined based on the data from main phase.

Norditropin® injected under the skin once a day.

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Height Velocity
Ramy czasowe: Baseline (week 0); week 26

Height velocity (HV) was derived from height measurements taken at baseline (week 0) and week 26 visit as: HV = (height at 26 weeks visit - height at baseline)/(time from baseline to 26 weeks visit in years). The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: from first administration and up until week 26 or last trial contact, whichever came first.

Baseline (week 0); week 26

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Change in Ratio of Bone Age Versus Chronological Age
Ramy czasowe: Baseline (week 0); week 52

Change in ratio of bone age (years) versus chronological age (years) from baseline (week 0) to week 52 is presented. X-rays of left hand and wrist for bone age assessment according to the Greulich and Pyle atlas were taken. X-ray images were sent to a central imaging laboratory for evaluation. Chronological Age (years) was calculated as: (Date minus Date of Birth) divided by 365.25. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: from first administration and up until week 52 or last trial contact, whichever came first.

Baseline (week 0); week 52
Change in Height Standard Deviation Score (HSDS)
Ramy czasowe: Baseline (week 0); week 26

Change in HSDS from baseline (week 0) to week 26 is presented. HSDS was derived using Centre for Disease Control and Prevention (CDC) standards. HSDS = [(height/population median)^skewness - 1]/(skewness * population standard deviation) where skewness, median and standard deviation is given by a reference growth table for the corresponding chronological age. The range for HSDS was -10 to +10. Negative scores indicated a height below the mean height for a child with the same age and gender, whereas positive scores indicated a height above the mean height for a child with the same age and gender. Positive value in change from baseline in HSDS indicated that HSDS was better than baseline HSDS In-trial observation period: from first administration and up until week 26 or last trial contact, whichever came first.

Baseline (week 0); week 26
Change in Height Velocity Standard Deviation Score (HVSDS)
Ramy czasowe: Baseline (week 0); week 26

Change in HVSDS from baseline (week 0) to week 26 is presented. HVSDS was derived using Prader standards. HV SDS was calculated using the formula: HV SDS = (height velocity - mean)/standard deviation (SD), where height velocity was the height velocity variable measured, mean and SD of height velocity by gender and age for the reference population. The range for HVSDS was -10 to +10. Negative scores indicated a height velocity below the mean height velocity for a child with the same age and gender, whereas positive scores indicated a height velocity above the mean height velocity for a child with the same age and gender. Positive value in change from baseline in HVSDS indicated that HVSDS was better than baseline HVSDS. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: from first administration and up until week 26 or last trial contact, whichever came first.

Baseline (week 0); week 26
Change in Fasting Plasma Glucose
Ramy czasowe: Baseline (week 0); week 26

Change in fasting plasma glucose from baseline (week 0) to week 26 is presented. The outcome measure was evaluated based on the data from on-treatment observation period. On-treatment observation period: from first administration and up until last trial contact, week 26 or 14 days after last administration, whichever came first.

Baseline (week 0); week 26
Change in Homeostatic Model Assessment for Steady State Beta Cell Function (HOMA-B)
Ramy czasowe: Baseline (week 0); week 26

Change in HOMA-B from baseline (week 0) to week 26 is presented. HOMA-B is a measure of the beta cell function and was calculated as follows: HOMA-B = (20 * fasting insulin (picomoles per liter [pmol/L]) * 1/6(microunit per milliliter [µU/mL]))/ FPG(mmol/L)-3.5). HOMA-beta score ranges from minus infinity to infinity (no limits). Higher score means better beta-cell function for HOMA-beta. Negative change from baseline (week 0) in HOMA-B indicated a worse outcome. The outcome measure was evaluated based on the data from on-treatment observation period. On-treatment observation period: from first administration and up until last trial contact, week 26 or 14 days after last administration, whichever came first.

Baseline (week 0); week 26
Change in Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)
Ramy czasowe: Baseline (week 0); week 26

Change in HOMA-IR from baseline (week 0) to week 26 is presented. Insulin resistance is a condition in which cells fail to respond to normal actions of hormone in body. HOMA-IR is calculated using a participant's fasting plasma insulin and glucose levels. HOMA-IR = fasting serum insulin (micro international units per milliliter (μU/ml)) × fasting plasma glucose (millimoles per liter (mmol/l)) / 22.5. HOMA-IR scores are classified as follows: less than 1.0: considered insulin sensitive, 0.5-1.4: considered healthy, above 1.8: considered early insulin resistance; above 2.7 is considered significant insulin resistance. HOMA-IR score ranges from 0-infinity (no upper limit). Higher the score, higher the level of insulin resistance. The outcome measure was evaluated based on the data from on-treatment observation period. On-treatment observation period: from first administration and up until last trial contact, week 26 or 14 days after last administration, whichever came first.

Baseline (week 0); week 26
Change in Glycated Haemoglobin (HbA1c)
Ramy czasowe: Baseline (week 0); week 26

Change in HbA1c from baseline (week 0) to week 26 is presented. The outcome measure was evaluated based on the data from on-treatment observation period. On-treatment observation period: from first administration and up until last trial contact, week 26 or 14 days after last administration, whichever came first.

Baseline (week 0); week 26
Change in Insulin-like Growth Factor I (IGF-I) Standard Deviation Score (SDS)
Ramy czasowe: Baseline (week 0); week 26

Change in IGF-I SDS from baseline (week 0) to week 26 is presented. IGF-I SDS was provided by the central laboratory; its calculation is based on the actual value of IGF-1 minus mean reference value of IGF-1 divided by reference standard deviation of IGF-1. The range for IGF-I SDS was from -10 to +10. Negative scores indicated a IGF-I below the mean IGF-I for a child with the same age and gender, whereas positive scores indicated a IGF-I above the mean IGF-I for a child with the same age and gender. Positive value in change from baseline in IGF-I SDS indicated that IGF-I SDS was higher than baseline IGF-I SDS. The outcome measure was evaluated based on the data from on-treatment observation period. On-treatment observation period: from first administration and up until last trial contact, week 26 or 14 days after last administration, whichever came first.

Baseline (week 0); week 26
Change in Insulin-like Growth Factor Binding Protein 3 (IGFBP-3) SDS
Ramy czasowe: Baseline (week 0); week 26

Change in IGFBP-3 SDS from baseline (week 0) to week 26 is presented. The range for IGFBP-3 SDS was from -10 to +10. Negative scores indicated a IGFBP-3 below the mean IGFBP-3 for a child with the same age and gender, whereas positive scores indicated a IGFBP-3 above the mean IGFBP-3 for a child with the same age and gender. Positive value in change from baseline in IGFBP-3 SDS indicated that IGFBP-3 SDS was higher than baseline IGFBP-3 SDS. The outcome measure was evaluated based on the data from on-treatment observation period. On-treatment observation period: from first administration and up until last trial contact, week 26 or 14 days after last administration, whichever came first.

Baseline (week 0); week 26

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Śledczy

  • Dyrektor Studium: Clinical Reporting Anchor and Disclosure 1452, Novo Nordisk A/S

Publikacje i pomocne linki

Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

4 lipca 2019

Zakończenie podstawowe (Rzeczywisty)

5 maja 2021

Ukończenie studiów (Szacowany)

23 grudnia 2026

Daty rejestracji na studia

Pierwszy przesłany

15 marca 2019

Pierwszy przesłany, który spełnia kryteria kontroli jakości

15 marca 2019

Pierwszy wysłany (Rzeczywisty)

18 marca 2019

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

6 października 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

5 października 2026

Ostatnia weryfikacja

1 października 2026

Więcej informacji

Terminy związane z tym badaniem

Inne numery identyfikacyjne badania

  • NN8640-4245
  • 2018 (Grant/umowa NIH USA)
  • U1111-1207-9741 (Inny identyfikator: World Health Organization (WHO))
  • 2018-000232-10 (Numer EudraCT)

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

TAK

Opis planu IPD

According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Tak

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .